What are the main reasons behind Eli Lilly's restructuring efforts?

Eli Lilly is undertaking these restructuring actions to increase company productivity, address current marketplace challenges (including the performance of Zyprexa in the U.S.), leverage prior investments, offset short-term challenges, and compete more effectively in a market with increasing pressure on pharmaceutical prices. The goal is to reduce cost structure and ensure sustainable long-term growth.

What is the estimated financial impact of these restructuring actions?

The company estimates total pretax charges for asset impairments, severance, and other costs to be in the range of $320 million to $420 million. Substantially all of these charges are expected to be reported in the fourth quarter of 2004. This includes an estimated $250 million to $320 million in non-cash charges (asset impairments) and $70 million to $100 million in cash expenditures (primarily severance and lease termination payments).

How will the research and development focus change?

Eli Lilly will concentrate its R&D efforts on the therapeutic areas of neuroscience, endocrine, oncology, and cardiovascular. The company will discontinue its efforts in inflammation and plans to close its RTP Laboratory site in Research Triangle Park, North Carolina, as many of its functions can be more efficiently handled at existing facilities in Indianapolis.

Why is Eli Lilly using non-GAAP financial measures in its reporting?

Eli Lilly uses non-GAAP financial measures, such as adjusted net income and diluted earnings per share, to provide investors with a more useful view of ongoing operations. These measures exclude items like asset impairment charges, charges for acquired in-process R&D, and restructuring charges, which are often variable and difficult to predict. Management believes these non-GAAP measures help investors evaluate performance, make period-over-period comparisons, and identify operating trends that might otherwise be masked by these excluded items.

LLY 8-K: Earnings & Results, Material Agreements & More

Summary

Eli Lilly & Co. (LLY) filed an 8-K on October 21, 2004, primarily to announce significant operational changes and financial results for the quarter ending September 30, 2004. The company detailed a substantial restructuring plan impacting research and development, manufacturing, and sales and marketing, which is expected to result in charges between $320 million and $420 million. These measures are aimed at increasing productivity, reducing costs, and adapting to market pressures, including those related to Zyprexa's performance in the U.S. Additionally, the filing disclosed amendments to the 2002 Lilly Stock Plan, extending its termination date and authorizing new award types like stock appreciation rights and stock units, though the compensation committee has no immediate plans for these new award types. The company also reported its third-quarter 2004 financial results and provided forward-looking guidance, emphasizing the use of non-GAAP measures to offer a clearer view of ongoing operations by excluding certain charges. Investors should note the significant restructuring costs anticipated in the fourth quarter of 2004.

Key Highlights

1Eli Lilly is implementing a significant restructuring plan across R&D, manufacturing, and sales/marketing, affecting nearly 1,000 U.S. positions.
2The company anticipates total pretax restructuring and asset impairment charges ranging from $320 million to $420 million, primarily to be recognized in Q4 2004.
3R&D focus will shift to neuroscience, endocrine, oncology, and cardiovascular, discontinuing efforts in inflammation and closing the RTP Laboratory site.
4Manufacturing operations at the Clinton, Indiana site will be narrowed to solely support the Elanco Animal Health business, ceasing human pharmaceutical production.
5Sales and marketing operations will be significantly streamlined by closing all U.S. district and regional sales offices, moving to a home-based model.
6The 2002 Lilly Stock Plan was amended to set a termination date of April 14, 2012, and expand authorized award types to include stock-settled stock appreciation rights and stock unit awards.
7Lilly is utilizing and explaining its use of non-GAAP financial measures (adjusted net income and EPS) to provide investors with a clearer view of ongoing operational performance, excluding specific charges.

ELI LILLY & Co 8-K Report, Material Agreement (Oct 21, 2004)

Summary

Key Highlights

Frequently Asked Questions